William Blair and Jefferies Maintain Outperform/Buy on Lantheus (LNTH) March 2026

On March 17, 2026, two major firms kept positive calls on Lantheus Holdings, Inc. The LNTH analyst rating picture shows William Blair maintained an Outperform rating and Jefferies maintained a Buy while raising its price target to $110. Both actions were logged the same day and came after a PDUFA date extension that William Blair called encouraging. These maintained ratings signal continued analyst confidence and give investors clear cues on near-term sentiment and expected upside.

LNTH analyst rating updates on March 17, 2026

William Blair maintained Outperform on Lantheus on March 17, 2026 at 05:13 PM and described the company as optimistic to receive approval after a PDUFA extension. See coverage from StreetInsider for details source.

Jefferies maintained Buy on Lantheus on March 17, 2026 at 03:08 PM and raised its price target to $110. The firm flagged valuation upside tied to pipeline milestones. Full Jefferies note at StreetInsider source.

What the LNTH analyst rating actions mean for investors

A maintained Outperform or Buy signals that analysts expect relative outperformance versus peers or the market. Investors should read the notes as continued conviction, not immediate guarantees.

Jefferies’ raised $110 price target represents a measurable upside case for holders if the market price sits below that level. Investors should weigh this upside against regulatory risks and clinical milestones.

Stock performance link to the LNTH analyst rating

The published entries show a price change since of -2.95% ($-2.37) on the reporting day, indicating the market reacted to news and timing despite positive ratings. Ratings can support buying interest, but short-term moves reflect many factors.

Lantheus has a market capitalization of $5,083,210,930, which frames how much capital the market assigns to its pipeline and revenue base. Analyst tone can shift flow into that market cap bucket quickly.

Price targets, valuation and risk with LNTH analyst rating context

Jefferies’ $110 price target is the only explicit target in these entries. A $110 target implies upside or downside depending on current market price and is a concrete benchmark for investors.

Regulatory timing and trial data drive valuation swings for Lantheus. William Blair flagged optimism around approval after a PDUFA delay, highlighting regulatory-readout risk and reward. Investors should match horizon and risk tolerance to those catalysts.

Historical analyst coverage and firm perspectives

Both William Blair and Jefferies are recurring coverage firms for life sciences and diagnostics names. Their maintained positive ratings continue a pattern of favorable views for Lantheus in recent coverage cycles.

That history matters: consistent positive coverage can support a valuation premium, while any future downgrades from these firms would likely move sentiment materially.

Practical investor checklist after LNTH analyst rating moves

Check regulatory calendar and upcoming catalysts before trading on rating headlines. Analysts cited the PDUFA extension and pipeline milestones as drivers of their views.

Use Jefferies’ $110 target as one scenario, but run sensitivity checks against revenue and approval probabilities. Remember that ratings are guidance, not trading rules.

Final Thoughts

Two notable firms maintained positive ratings on Lantheus Holdings, Inc. on March 17, 2026, reinforcing current analyst confidence. The LNTH analyst rating set shows William Blair holding Outperform and Jefferies keeping Buy while lifting its price target to $110. Those signals support a constructive outlook, but they do not remove regulatory or execution risk. The market reaction that day was a -2.95% ($-2.37) price change, a reminder that ratings and short-term price moves can diverge.

Meyka AI rates LNTH with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Investors should treat the maintained ratings as inputs, not advice. Use the Jefferies price target and William Blair’s regulatory view to frame upside scenarios and downside cases, and align trades to your risk tolerance and time horizon. Meyka AI provides this snapshot as an AI-powered market analysis platform and not as investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.